CN117085140A - 表面活性剂肽纳米结构及在药物递送中的用途 - Google Patents

表面活性剂肽纳米结构及在药物递送中的用途 Download PDF

Info

Publication number
CN117085140A
CN117085140A CN202311055643.1A CN202311055643A CN117085140A CN 117085140 A CN117085140 A CN 117085140A CN 202311055643 A CN202311055643 A CN 202311055643A CN 117085140 A CN117085140 A CN 117085140A
Authority
CN
China
Prior art keywords
peptide
seq
amino acid
sirna
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311055643.1A
Other languages
English (en)
Chinese (zh)
Inventor
埃尔顿·阿列斯金
吉恩锡
松田宪昭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3D Matrix Ltd
Original Assignee
3D Matrix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3D Matrix Ltd filed Critical 3D Matrix Ltd
Publication of CN117085140A publication Critical patent/CN117085140A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202311055643.1A 2017-12-15 2018-11-30 表面活性剂肽纳米结构及在药物递送中的用途 Pending CN117085140A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762599566P 2017-12-15 2017-12-15
US62/599,566 2017-12-15
PCT/IB2018/001511 WO2019116092A1 (en) 2017-12-15 2018-11-30 Surfactant peptide nanostructures and uses in drug delivery
CN201880089258.XA CN111712230B (zh) 2017-12-15 2018-11-30 表面活性剂肽纳米结构及在药物递送中的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880089258.XA Division CN111712230B (zh) 2017-12-15 2018-11-30 表面活性剂肽纳米结构及在药物递送中的用途

Publications (1)

Publication Number Publication Date
CN117085140A true CN117085140A (zh) 2023-11-21

Family

ID=65276214

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311055643.1A Pending CN117085140A (zh) 2017-12-15 2018-11-30 表面活性剂肽纳米结构及在药物递送中的用途
CN201880089258.XA Active CN111712230B (zh) 2017-12-15 2018-11-30 表面活性剂肽纳米结构及在药物递送中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880089258.XA Active CN111712230B (zh) 2017-12-15 2018-11-30 表面活性剂肽纳米结构及在药物递送中的用途

Country Status (6)

Country Link
US (2) US11324703B2 (https=)
EP (1) EP3723726A1 (https=)
JP (3) JP2021506815A (https=)
CN (2) CN117085140A (https=)
IL (1) IL275380A (https=)
WO (1) WO2019116092A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021506815A (ja) 2017-12-15 2021-02-22 株式会社スリー・ディー・マトリックス 界面活性ペプチドナノ構造および薬物送達における使用
EP3754336B1 (en) * 2018-02-15 2024-01-17 3-D Matrix, Ltd. Cancer lesion tissue evaluation for optimizing effect of boron neutron capture therapy
US20250059231A1 (en) * 2021-09-30 2025-02-20 Protinhi B.V. Protease inhibitors

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582640A (en) 1982-03-08 1986-04-15 Collagen Corporation Injectable cross-linked collagen implant material
US4466641A (en) 1982-08-04 1984-08-21 The Lockformer Company Duct connecting system
US4642117A (en) 1985-03-22 1987-02-10 Collagen Corporation Mechanically sheared collagen implant material and method
US4947840A (en) 1987-08-21 1990-08-14 Massachusetts Institute Of Technology Biodegradable templates for the regeneration of tissues
US5236903A (en) 1988-06-24 1993-08-17 Ichiro Azuma Polypeptide comprising repeated cell-adhesive core sequences
US5110604A (en) 1988-06-30 1992-05-05 Collagen Corporation Processes for producing collagen matrixes and methods of using same
US5126141A (en) 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
US5550187A (en) 1988-11-21 1996-08-27 Collagen Corporation Method of preparing crosslinked biomaterial compositions for use in tissue augmentation
US5629291A (en) 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
US5292514A (en) 1992-06-24 1994-03-08 Minnesota Mining And Manufacturing Company Azlactone-functional substrates, corneal prostheses, and manufacture and use thereof
US5670483A (en) 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5955343A (en) 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
GB2274988A (en) 1993-02-10 1994-08-17 Mcconn Stern Rita Iodine containing wound-healing preparations
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5773577A (en) 1994-03-03 1998-06-30 Protein Polymer Technologies Products comprising substrates capable of enzymatic cross-linking
US5527610A (en) 1994-05-20 1996-06-18 The Uab Research Foundation Elastomeric polypeptide matrices for preventing adhesion of biological materials
US5510102A (en) 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
EP0874910A4 (en) 1995-06-07 1999-04-21 Life Technologies Inc ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
WO1996040033A1 (en) 1995-06-07 1996-12-19 Clarion Pharmaceuticals Inc. Non-biological patch for hemostasis
CZ318998A3 (cs) 1996-04-04 1999-09-15 Baxter Aktiengesellschaft Hemostatická houba na bázi kolagenu, způsob její přípravy, kryt na ránu a kit k přípravě tohoto krytu
US6489446B1 (en) 1996-08-07 2002-12-03 Hsc Research And Development Limited Partnership Self-aligning peptides modeled on human elastin and other fibrous proteins
US6083522A (en) 1997-01-09 2000-07-04 Neucoll, Inc. Devices for tissue repair and methods for preparation and use thereof
US6224893B1 (en) 1997-04-11 2001-05-01 Massachusetts Institute Of Technology Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
US6428811B1 (en) 1998-03-11 2002-08-06 Wm. Marsh Rice University Temperature-sensitive polymer/nanoshell composites for photothermally modulated drug delivery
US6046160A (en) 1999-07-22 2000-04-04 Deroyal Industries, Inc. Composition and method for enhancing wound healing
ATE389416T1 (de) 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
JP4104462B2 (ja) 2001-01-25 2008-06-18 ニコメド ファーマ エイエス コラーゲンスポンジを調製する方法、コラーゲンフォームの一部を抽出するための装置、および伸長したコラーゲンスポンジ
US7449180B2 (en) 2001-02-06 2008-11-11 John Kisiday Macroscopic scaffold containing amphiphilic peptides encapsulating cells
DE60230593D1 (de) 2001-02-06 2009-02-12 Massachusetts Inst Technology Peptidgerüstverkapselung von gewebszellen und verwendungen davon
US7179784B2 (en) 2001-07-10 2007-02-20 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
AU2003222167A1 (en) 2002-04-02 2003-10-20 Northwestern University Peptide amphiphile solutions and self assembled peptide nanofiber networks
WO2003095972A2 (en) 2002-05-09 2003-11-20 The Regents Of The University Of California Method of analyzing ataxia-telangiectasia protein
AU2003249606A1 (en) 2002-05-13 2003-12-02 Massachusetts Institute Of Technology Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof
GB0216286D0 (en) 2002-07-15 2002-08-21 Univ Leeds Network
EP1542709A2 (en) 2002-08-06 2005-06-22 EPIX Pharmaceuticals, Inc. Peptide aggregates
US7713923B2 (en) 2003-06-25 2010-05-11 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
EP2711025A3 (en) 2003-06-25 2014-09-10 Massachusetts Institute of Technology Self-assembling peptides incorporating modifications and methods of use thereof
GB0404374D0 (en) 2004-02-27 2004-03-31 Univ Manchester Treatment of bacterial infections
JP5255274B2 (ja) 2004-07-06 2013-08-07 スリーディー マトリックス， インコーポレイテッド 精製両親媒性ペプチド組成物およびその使用
JP2008526749A (ja) 2005-01-04 2008-07-24 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 自己アセンブリするペプチドナノファイバーを用いたｐｄｇｆの徐放性の送達
DK1879606T3 (da) 2005-04-25 2013-09-23 Massachusetts Inst Technology Selvorganiserende peptider til fremme af hæmostase
US9162005B2 (en) 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
JP4982841B2 (ja) 2005-10-12 2012-07-25 国立大学法人名古屋大学 再生医療骨組成物
US8796544B2 (en) 2005-12-14 2014-08-05 Massachusetts Institute Of Technology Bio-sensitized solar cells (BSSC)
ES2673947T3 (es) 2006-04-25 2018-06-26 Massachusetts Institute Of Technology Composiciones y métodos para afectar al movimiento de contaminantes, líquidos corporales u otras entidades y/o afectar a otras condiciones fisiológicas
WO2008039483A2 (en) 2006-09-26 2008-04-03 Massachusetts Institute Of Technology Modified self-assembling peptides
WO2008073392A2 (en) 2006-12-11 2008-06-19 3D Matrix, Inc. Compositions and methods for cardiac tissue protection and regeneration
US9415084B2 (en) 2007-03-14 2016-08-16 Arch Biosurgery, Inc. Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
US20090069547A1 (en) * 2007-05-01 2009-03-12 Massachusetts Institute Of Technology Stabilization of mammalian membrane proteins by short surfactant peptides
WO2008136820A1 (en) 2007-05-01 2008-11-13 Massachusetts Institute Of Technology Stabilization of mammalian membrane proteins by short surfactant peptides
US9714941B2 (en) 2007-07-31 2017-07-25 Massachusetts Institute Of Technology Bio-sensing nanodevice
WO2010014903A1 (en) 2008-07-31 2010-02-04 Massachusetts Institute Of Technology Multiplexed olfactory receptor-based microsurface plasmon polariton detector
US9133484B2 (en) 2008-08-27 2015-09-15 3-D Matrix, Ltd. Transfection agent
RU2011118341A (ru) 2008-10-06 2012-11-20 3-Д Матрикс, Лтд. (Jp) Агент для окклюзии тканей
CN101514225B (zh) 2008-10-13 2011-09-14 西安蓝晶生物科技有限公司 自聚体多肽及其制备方法和应用
JP2010222338A (ja) * 2009-02-27 2010-10-07 Three D Matrix:Kk 核酸移送担体
CN105664223B (zh) * 2009-10-26 2018-12-04 日产化学工业株式会社 化妆料、皮肤外用剂、以及医疗用仪器
US9439941B2 (en) 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
JP2011126855A (ja) 2009-12-15 2011-06-30 Three D Matrix:Kk タンパク質の凝集抑制剤
US20130236891A1 (en) 2010-08-20 2013-09-12 3-D Matrix, Ltd. Method and composition for the treatment, prevention, and diagnosis of cancer containing or derived from cancer stem cells
US9149511B2 (en) 2011-06-30 2015-10-06 Ethicon, Inc. Procoagulant peptides and their derivatives and uses therefor
WO2013181511A1 (en) * 2012-05-31 2013-12-05 Massachusetts Institute Of Technology Sustained delivery of molecules using peptide surfactants and uses thereof
GB2503701B (en) 2012-07-04 2015-08-26 Shameem Anthony Carl Sampath Limb exercise device
WO2014008400A2 (en) 2012-07-06 2014-01-09 3-D Matrix, Inc. Fill-finish process for peptide solutions
US9140677B2 (en) 2012-08-13 2015-09-22 Massachusetts Institute Of Technology Methods and apparatus for artificial olfaction
SG11201506232VA (en) 2013-03-06 2015-09-29 3D Matrix Ltd Surgical methods employing purified amphiphilic peptide compositions
ES2756531T3 (es) 2013-08-22 2020-04-27 Arch Biosurgery Inc Mallas implantables para controlar el movimiento de fluidos
RU2016139369A (ru) 2014-03-10 2018-04-10 3-Д Матрикс, Лтд. Композиции самоорганизующихся пептидов
JP6554121B2 (ja) 2014-03-10 2019-07-31 株式会社スリー・ディー・マトリックス 気管支閉鎖剤としての自己組織化ペプチド
EP3116522B1 (en) 2014-03-10 2019-05-08 3-D Matrix Ltd. Autoassembling peptides for the treatment of pulmonary leakage
US10245299B2 (en) 2014-03-10 2019-04-02 3-D Matrix, Ltd. Autoassembling peptides for the treatment of pulmonary bulla
BR112016019510A2 (pt) 2014-03-10 2017-10-24 3 D Matrix Ltd esterilização e filtração de composições de peptídeos
PL229030B1 (pl) 2014-03-13 2018-05-30 Zygmunt Jerzy Szymański Nanopreparat bakteriobójczy
JP2014208669A (ja) 2014-06-17 2014-11-06 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
JP2016028102A (ja) 2015-10-21 2016-02-25 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
US10814038B2 (en) 2016-01-06 2020-10-27 3-D Matrix, Ltd. Combination compositions
WO2017164334A1 (ja) 2016-03-23 2017-09-28 公益財団法人 川崎市産業振興財団 ホウ素クラスター結合ペプチド化合物
WO2018097335A1 (ja) 2016-11-25 2018-05-31 国立大学法人 岡山大学 ホウ素中性子捕捉療法のための新規ｂｓｈ複合体
WO2019093308A1 (ja) 2017-11-09 2019-05-16 国立大学法人広島大学 ｍｉＲＮＡを含むがん治療用医薬組成物
JP2021506815A (ja) 2017-12-15 2021-02-22 株式会社スリー・ディー・マトリックス 界面活性ペプチドナノ構造および薬物送達における使用

Also Published As

Publication number Publication date
JP7760174B2 (ja) 2025-10-27
CN111712230B (zh) 2024-04-26
JP2025028940A (ja) 2025-03-05
US20190231706A1 (en) 2019-08-01
US12239744B2 (en) 2025-03-04
WO2019116092A1 (en) 2019-06-20
CN111712230A (zh) 2020-09-25
EP3723726A1 (en) 2020-10-21
US11324703B2 (en) 2022-05-10
IL275380A (en) 2020-07-30
JP2023076699A (ja) 2023-06-01
US20220249392A1 (en) 2022-08-11
JP2021506815A (ja) 2021-02-22

Similar Documents

Publication Publication Date Title
JP7760174B2 (ja) 界面活性ペプチドナノ構造および薬物送達における使用
Lai et al. Self-assembling peptide dendron nanoparticles with high stability and a multimodal antimicrobial mechanism of action
JP6698756B2 (ja) 細胞に分子を送達する方法及び担体複合体
Katyal et al. Self-assembled protein-and peptide-based nanomaterials
US8747903B2 (en) Composition for nucleic acid delivery using metal nanoparticles and preparing method thereof
Yoo et al. Biodegradable nanoparticles containing protein‐fatty acid complexes for oral delivery of salmon calcitonin
EP3059242A1 (en) Alpha helix cell-penetrating peptide multimer, preparation method therefor and use thereof
CN104837859B (zh) 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
CA2900628C (en) Nanoparticle delivery compositions
EP2308900B1 (en) Immunogenic compositions and methods of use
Breger et al. Nanoparticle cellular uptake by dendritic wedge peptides: achieving single peptide facilitated delivery
JP2001512739A (ja) 抗生作用ペプチドから誘導される線状ペプチド、製法および活性物質を仲介する用途
Krauson et al. Synthetic molecular evolution of pore-forming peptides by iterative combinatorial library screening
Kumari et al. Surface-engineered mucus penetrating nucleic acid delivery systems with cell penetrating peptides for the lungs
Kaygisiz et al. Peptide amphiphiles as biodegradable adjuvants for efficient retroviral gene delivery
Huang et al. Peptide-based assembled nanostructures that can direct cellular responses
Zakeri-Milani et al. Cytotoxicity and immunogenicity evaluation of synthetic cell-penetrating peptides for methotrexate delivery
WO2015057820A2 (en) Peptide constructs and well-defined aggregates thereof
KR101336552B1 (ko) 전립선암 특이적 ｓｉＲＮＡ 전달체
JPH08504210A (ja) 結合生物活性ペプチドを使用した敗血症性ショックの治療
JP2006117602A (ja) 導電性ペプチドナノファイバー及びその製造方法
CN106039321A (zh) 利妥昔单抗/氧化石墨烯复合抗体、制备方法及应用
CN117069799B (zh) 细胞穿膜肽及其应用
WO2023014293A2 (en) A ph-responsive composition for facilitating delivery of a cargo and a method of encapsulating cargo with a ph-responsive composition
Mazza Peptide nanofibres for drug delivery.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination